» Articles » PMID: 37126595

Vascular Contribution to Lung Repair and Fibrosis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Lungs are constantly exposed to environmental perturbations and therefore have remarkable capacity to regenerate in response to injury. Sustained lung injuries, aging, and increased genomic instability, however, make lungs particularly susceptible to disrepair and fibrosis. Pulmonary fibrosis constitutes a major cause of morbidity and is often relentlessly progressive, leading to death from respiratory failure. The pulmonary vasculature, which is critical for gas exchanges and plays a key role during lung development, repair, and regeneration, becomes aberrantly remodeled in patients with progressive pulmonary fibrosis. Although capillary rarefaction and increased vascular permeability are recognized as distinctive features of fibrotic lungs, the role of vasculature dysfunction in the pathogenesis of pulmonary fibrosis has only recently emerged as an important contributor to the progression of this disease. This review summarizes current findings related to lung vascular repair and regeneration and provides recent insights into the vascular abnormalities associated with the development of persistent lung fibrosis.

Citing Articles

Multiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease.

Leonard-Duke J, Agro S, Csordas D, Bruce A, Eggertsen T, Tavakol T PNAS Nexus. 2024; 4(1):pgae551.

PMID: 39720203 PMC: 11667245. DOI: 10.1093/pnasnexus/pgae551.


Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis.

Raslan A, Pham T, Lee J, Kontodimas K, Tilston-Lunel A, Schmottlach J Nat Commun. 2024; 15(1):5449.

PMID: 38937456 PMC: 11211333. DOI: 10.1038/s41467-024-49545-x.


The role of vasculature and angiogenesis in respiratory diseases.

Ackermann M, Werlein C, Plucinski E, Leypold S, Kuhnel M, Verleden S Angiogenesis. 2024; 27(3):293-310.

PMID: 38580869 PMC: 11303512. DOI: 10.1007/s10456-024-09910-2.


Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.

Adegunsoye A, Kropski J, Behr J, Blackwell T, Corte T, Cottin V Am J Respir Crit Care Med. 2024; 210(4):401-423.

PMID: 38573068 PMC: 11351799. DOI: 10.1164/rccm.202401-0238SO.


Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.

Leonard-Duke J, Agro S, Csordas D, Bruce A, Eggertsen T, Tavakol T bioRxiv. 2024; .

PMID: 38559112 PMC: 10979947. DOI: 10.1101/2024.03.15.585249.


References
1.
Mora A, Rojas M, Pardo A, Selman M . Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov. 2017; 16(11):810. PMC: 5815310. DOI: 10.1038/nrd.2017.225. View

2.
Hashimoto N, Phan S, Imaizumi K, Matsuo M, Nakashima H, Kawabe T . Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009; 43(2):161-72. PMC: 2937229. DOI: 10.1165/rcmb.2009-0031OC. View

3.
Shea B, Probst C, Brazee P, Rotile N, Blasi F, Weinreb P . Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight. 2017; 2(9). PMC: 5414562. DOI: 10.1172/jci.insight.86608. View

4.
Mogulkoc N, Brutsche M, Bishop P, Murby B, Greaves M, Horrocks A . Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax. 2001; 56(12):916-23. PMC: 1745984. DOI: 10.1136/thorax.56.12.916. View

5.
McKeown S, Richter A, OKane C, McAuley D, Thickett D . MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2008; 33(1):77-84. DOI: 10.1183/09031936.00060708. View